The global Cell-free fetal DNA testing market is estimated to be valued at USD 1,687.8 million in 2025 and is projected to reach USD 3,051.5 million by 2035, registering a compound annual growth rate ...

The global cell-free fetal DNA testing market is experiencing robust growth, with revenue projected to climb from USD 1,566.0 million in 2024 to USD 3,051.5 million by 2035, advancing at a CAGR of 6.1 ...

The COVID-19 pandemic thrust messenger RNA (mRNA) into the spotlight, underscoring its promise as a nimble, programmable platform for delivering genetic instructions directly to cells. The success of ...

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...

Exploratory analyses of immune reconstitution biomarkers from a Ph1b study of an investigational, oral, live biotherapeutic, SER-155, in adult allo-HCT. The impact of the use of hypomethylating agents ...

DEAR DR. ROACH: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? -- M.N. ANSWER: When screening patients ...

When cells in the body die, they release DNA. This DNA, known as cell-free DNA (cfDNA), makes its way into the bloodstream where it gets chopped up by enzymes, and in minutes to hours, the liver pulls ...

Professor Norikazu Ichihashi and his colleagues at the University of Tokyo have successfully induced gene expression from a DNA, characteristic of all life, and evolution through continuous ...